- Acumen Powered by Robins Kaplan LLP®
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 17, 2024Emily Tremblay Named IP Rising Star by Euromoney in 2024 Women in Business Law Awards
-
June 17, 2024Three Robins Kaplan Partners Named BTI Client Service All-Stars
-
June 13, 2024Brendan Johnson Named South Dakota Trial Lawyer of The Year
-
June 27, 2024Sex Abuse Litigation
-
June 10-11, 20242024 Probate and Trust Law Section Conference
-
June 11, 2024FBA 2024 Federal Practice Seminar
-
June 2024Robins Kaplan Secures Landmark $7.75 Million Verdict in Aerosol Duster Misuse Case
-
June 2024To Seize or Not to Seize: Campus Protests and Police Uses of Force
-
June 2024Communicating Your Estate Plan: A Helpful Tool, Not a Fix-All
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Pfizer Inc. v. Alkem Labs. Ltd.
Failure to raise a claim-construction issue precludes a party from arguing claim differentiation.
October 15, 2015
![GENERICally Speaking: A Hatch Waxman Litigation Bulletin](/-/media/images/newsletters/generically-speaking-social-graphics/generically-speaking-nwsltr-badge.jpg?la=en&h=160&w=390&la=en&hash=314B8432ED62E0647D7FC4565EC18B79)
Case Name: Pfizer Inc. v. Alkem Labs. Ltd., Civ. No. 13-1110-GMS, 2015 U.S. Dist. LEXIS 94327 (D. Del. July 21, 2015) (Sleet, J.)
Drug Product and Patent(s)-in-Suit: Toviaz® (fesoterodine); U.S. Patents Nos. 7,384,980 ("the '980 patent") and 7,855,230 ("the '230 patent")
Nature of the Case and Issue(s) Presented: The parties conducted a bench trial on the infringement of one claim from each patent. The patents cover the pharmaceutical composition for Toviaz, a drug to help treat symptoms of an overactive bladder.
Sandoz, the only defendant challenging infringement, argued that Pfizer’s expert failed in his expert report to opine on the standard for one of skill in the art, and thus was precluded from offering opinions as to claim construction. Sandoz further argued that the doctrine of claim differentiation required the scope of the claims to be narrowed to support a finding of non-infringement.
Pfizer argued that Sandoz had waived any argument as to the scope of testimony for its expert by failing to raise the issue at the pre-trial conference. As for claim differentiation, Pfizer argued that Sandoz failed to offer any contrary claim constructions in order to invoke an argument on claim differentiation.
The district court found that Sandoz had waived any argument as to the expert’s testimony and failed to offer claim-construction proposals to raise an issue of claim differentiation.
Why Pfizer Prevailed: The district court found that Sandoz had waived any argument as to the scope of Pfizer’s expert’s testimony. The court noted that Sandoz had raised the issue in its pre-trial briefing, but failed to address the issue when the court asked about it during the pre-trial conference.
The district court rejected Sandoz’s argument on claim differentiation because Sandoz had failed to raise a claim-construction issue. The court noted that there may have been a colorable argument on claim construction, but Sandoz did not offer any expert testimony on how one of skill would read the claim or ask the court to construe the claim. Thus, the record did not support a claim-differentiation argument.
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.